Lamm WL, Porias CH, Cantellano OM, Mata P, Morales MG, Pacheco GC, Calderón FF

Language: Spanish
References: 10
Page: 12-18
PDF size: 414.68 Kb.

ABSTRACT

Objectives: To evaluate bone mineral density after 12 month treatment with Alendronato, 70 mg vs. Calcitriol 0.25 mcg/day in men with androgen deprivation due to advanced prostate cancer.
Material and Methods: 105 men with advanced prostate cancer treated with androgen deprivation, who were randomized to receive either Alendronato 70 mg every 7 days or Calcitriol 0.25 mcg daily for a 12 month. Initial and annual bone densitometry of lumbar column and hip was performed. Trimester values of serum osteocalcin and alkaline phosphatase were also determined.
Results: 36% (n= 38) had lumbar osteoporosis with mean T score -3.27 SD and bone mineral density 0.726 gr/cm2. Additionally, 31.5% of this patients coexisted with hip osteoporosis (average T score -3.35 SD). Correlation between osteoporosis incidence with Gleason score and bone metastases was observed. The Alendronato group (n= 49) showed a significant reduction in bone loss activity, reflected by better bone mineral density, T score and serum osteocalcin and alkaline phosphatase levels. Contrary, the Calcitriol group (n= 56) showed no response and a worsening of the bone loss activity after 12 months.
Conclusions: Alendronato treatment prevents accelerated bone loss and it’s more efficient than the Calcitriol treatment. We found that associated androgen deprivation Osteoporosis incidence is similar to that reported in world literature.

REFERENCES

1. Wei T. John, Gross Milton. Androgen Deprivation Therapy for Prostate Cancer Results in Significant Loss of Bone Density. Urology. 1999;(54):607-611.

2. Del Rio L. Técnicas de medición de masa ósea. Rev Esp Enf Met Óseas. 1998;7(Supl A):1-3.

3. Moyad A. Mark. Complementary therapies for Reducing the Risk of Osteoporosis in Patientes Receiving Luteinizing Hormone-Releasing Hormone treatment/ orchiectomy for Prostate Cancer: A Review and Assesment of the Need for more Research. Urology. 2002;(59)(Suppl 4A):34-40.

4. Bilezikian JP, Morishima A, Bell J. Increased bone mass as a result of estrogen therapy in a man with aromatase deficiency. N Engl J Med. 1998;(339): 599-603.

5. Townsend MF, Sanders WH, Northway RO, et al. Bone fractures associated with lutenizing hormone-releasing hormone agonists used in the treatment of prostate cancer. Cancer. 1997;(79):545-550.

6. Daniell HH. Osteoporosis after orchiectomy for prostate cancer. J Uro. 1997;(157):439-444.

7. Juan Morote, Youssef. Increase of Bone Alkaline Phosphatase After Androgen Deprivation Therapy in Patientes With Prostate Cancer. Urology. 2002;(59): 277-280.

8. Eriksson S, Eriksson A, Stege R, et al. Bone mineral density in patients with prostatic cancer treated with orchidectomy and with estrogens. Calcif Tissue Int. 1995;(57):97-99.

9. Smith R. Matthew. Osteoporosis during androgen deprivation therapy for prostate cancer. Urology. 2002;(60)(Suppl 3:A):79-86, 2002.

10. Broulik PD, Straka L. Effect of antiandrogens Casodex and epitestosterone on bone composition in mice. Broulik PD, Straka L. Bone. 1997;(20):473-475.